Intratumoral TLR4 agonist therapy elicits antigen-specific T cell clonal expansion in metastatic leiomyosarcoma: a case series.
Saved in:
| Title: | Intratumoral TLR4 agonist therapy elicits antigen-specific T cell clonal expansion in metastatic leiomyosarcoma: a case series. |
|---|---|
| Authors: | Zhang JS; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Ng JCK; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Hermida de Viveiros P; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Al-Marayaty R; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Al Akoum N; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Shinglot H; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Jing W; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Vizcaino V; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Alexiev BA; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Cranmer LD; Department of Medicine, City of Hope Cancer Center, Los Angeles, CA, United States., Loggers ET; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, United States., Abrams H; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, United States., Wagner MJ; Sarcoma Center, Dana Farber Cancer Institute, Boston, MA, United States., Pillarisetty VG; Department of Surgery, University of Washington, Seattle, WA, United States., Kim EY; Department of Radiation Oncology, University of Washington, Seattle, WA, United States., Pierce RH; Attivare, Natick, MA, United States., Berglund P; HDT Bio, Seattle, WA, United States., Jones RL; Royal Marsden and Institute for Cancer Research, London, United Kingdom., Lu H; Pfizer, Bothell, WA, United States., Ter Meulen J; Obsidian Therapeutics, Cambridge, MA, United States., Pollack SM; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Seo YD; Department of Surgery, University of Washington, Seattle, WA, United States.; Department of Surgical Oncology, Medical College of Wisconsin, Milwaukee, WI, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2026 May 20; Vol. 16, pp. 1829331. Date of Electronic Publication: 2026 May 20 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2026.1829331 |
